OSMT Osmotica Pharmaceuticals plc

6.51
-0.07  -1%
Previous Close 6.58
Open 6.62
Price To Book 2.38
Market Cap 338,039,061
Shares 51,926,123
Volume 199,315
Short Ratio
Av. Daily Volume 118,709
Stock charts supplied by TradingView

NewsSee all news

  1. Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Acceptance of New Drug Application by FDA for RVL-1201 (Oxymetazoline Hydrochloride Ophthalmic Solution, 0.1%) for Acquired Blepharoptosis (Droopy Eyelid)

    BRIDGEWATER, N.J., Nov.

  2. Osmotica Pharmaceuticals plc Reports Third Quarter 2019 Results

    Third quarter 2019 total revenue of $65.5 million Submitted NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, to FDA BRIDGEWATER, N.J, Nov. 14,

  3. Osmotica Pharmaceuticals plc to Provide Third Quarter 2019 Business and Financial Update on November 15, 2019

    BRIDGEWATER, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release

  4. Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors

    BRIDGEWATER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical company, today announced the

  5. Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid)

    BRIDGEWATER, N.J., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date July 16, 2020.
RVL-1201
Blepharoptosis
Phase 3 data March 27, 2019 noted one of two endpoints met.
Ontinua ER
Spasticity resulting from multiple sclerosis

Latest News

  1. Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Acceptance of New Drug Application by FDA for RVL-1201 (Oxymetazoline Hydrochloride Ophthalmic Solution, 0.1%) for Acquired Blepharoptosis (Droopy Eyelid)

    BRIDGEWATER, N.J., Nov.

  2. Osmotica Pharmaceuticals plc Reports Third Quarter 2019 Results

    Third quarter 2019 total revenue of $65.5 million Submitted NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, to FDA BRIDGEWATER, N.J, Nov. 14,

  3. Osmotica Pharmaceuticals plc to Provide Third Quarter 2019 Business and Financial Update on November 15, 2019

    BRIDGEWATER, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release

  4. Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors

    BRIDGEWATER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical company, today announced the

  5. Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid)

    BRIDGEWATER, N.J., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical

  6. Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-1201

    BRIDGEWATER, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical

  7. Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting

    BRIDGEWATER, N.J., Sept. 4, 2019 /PRNewswire/ -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical company, today announced results of the

  8. Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference

    BRIDGEWATER, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ:OSMT), a fully integrated biopharmaceutical company, today announced that Andrew Einhorn, Chief